Programmable Cell Therapy

Scroll

ArsenalBioCellTherapy CloudComputing ComputationalBiology GenomeEngineering MachineLearning SoftwareEngineering SyntheticImmunology

ArsenalBio was founded to discover, develop and commercialize curative immune cell therapies

Board of Directors

Brook Byers

Ken Drazan MD

Matt Fust

Barbara Kosacz

Alexander Marson MD PhD

Sean Parker

Beth Seidenberg MD

Leadership Team

Ken Drazan MD
Chairman, CEO, Co-founder

Susie Jun MD PhD
Chief Medical Officer

Tarjei Mikkelsen PhD
Chief Technology Officer

Bee Nguyen
Chief People Officer

John Schroer
Chief Financial Officer

Tim Sirichoke
Chief Technical Operations Officer

Meg Nibbi JD
Chief Legal Officer

W. Nicholas Haining BM BCh
Chief Scientific Officer

Science Founders

Brad Bernstein MD PhD

W. Nicholas Haining BM BCh

Alexander Marson MD PhD

Theo Roth MD PhD

Kole T. Roybal PhD

E. John Wherry PhD

Scientific Advisors

Howard Y. Chang PhD

Elaine Fuchs PhD

Zemin Zhang PhD

Ananda Goldrath PhD

Cameron Turtle MBBS PhD

Investors

News

October 12, 2021 / Winners of the 3rd Annual UCSF Health Awards Announced at Grand Finale at the Chase Center at Mission Bay in San Francisco. /

July 19, 2021 / ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer Paradigm to Discover and Develop Immune Cell Therapies /

Mar 8, 2021 / ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer /

Jan 7, 2021 / ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors. /

Oct 17, 2019 / ArsenalBio Launches With $85 Million Series A Financing to Advance New Paradigm to Discover and Develop Immune Cell Therapies /